Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
The assessment of response to therapy in prostate cancer (PCa) patients is an ongoing, open issue. Prostate-specific antigen has limitations, especially in advanced metastatic PCa, which often displays intratumor variability in terms of response to therapy. Conventional imaging (i.e. computerized to...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2024-10-01
|
| シリーズ: | Therapeutic Advances in Medical Oncology |
| オンライン･アクセス: | https://doi.org/10.1177/17588359241258367 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|